{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097615","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.249504+00:00","generated_at":"2026-05-15T18:06:19.852721+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyell Immunopharma appoints Smital Shah as Chief Financial and Business Officer","bullets":["Smital Shah appointed CFO and principal financial officer, effective March 9, 2026.","Initial base salary $500,000; target annual bonus up to 50% of base salary.","Granted option for 140,000 shares under 2021 Equity Incentive Plan; vesting 25% at 1 year then monthly.","Shah previously provided consulting to Lyell since Feb 2026; prior roles at ProQR, Gilead, and investment banks.","Will participate in Officer Severance Plan as Tier I Employee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097615","json":"https://secwatch.observer/filing/0001193125-26-097615.json","markdown":"https://secwatch.observer/filing/0001193125-26-097615.md","text":"https://secwatch.observer/filing/0001193125-26-097615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526097615/0001193125-26-097615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526097615/d84786d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:06:19.852721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}